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ABSTRACT 
Objective: Drug delivery to the colon via oral route can be directly treated a variety of diseases in the colon, such as fibrosis. Tetrandrine is a drug 
that has anti-fibrosis effects. In this study, chitosan-tripolyphosphate (TPP) beads containing tetrandrine was made and evaluated for in vitro 
release profile and in vivo targeted test. 
Methods: Chitosan-TPP tetrandrine beads were prepared by ionic gelation method with variation in sodium tripolyphosphate concentration: 3% 
(Formula 1), 4% (Formula 2), and 5% (Formula 3). All formulae were characterized for its morphology, particle size, moisture content, process 
efficiency, entrapment efficiency, thermal character, crystallinity, and swelling. Then, the best formula was coated with HPMCP HP-55, CAP, Eudragit 
L100-55, or Eudragit L100 prior to drug release profile in vitro and in vivo test. 
Results: Beads from all formulae had an average size: 920.50±0.04 µm, 942.21±0.08 µm, and 1085.95±0.03 µm; Water content: 7.28±0.003%, 
5.64±0.005%, and 6.84±0.004%; Process efficiency: 29.70%, 28.96%, and 29.70%; Entrapment efficiency: 16.20±0.63%, 17.02±0.37%, and 
20.42±0.70% for Formula 1, 2, and 3, respectively. In addition, the results of in vitro cumulative drug release were 67.36%, 76.04%, 83.12%, 
83.21%, 40.16%, 37.98%, 45.86%, 41.71% for Formula 3A-3H, respectively. 
Conclusion: It can be concluded that Formula 3D (CAP 15%) was chosen as a formulation with the best in vitro profile. Moreover, the in vivo 
targeted test showed that Formula 3D was able to deliver the beads to the intestine compared to the control beads. 
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The colon is one of the most important organs in the human body's 
digestive system. In the treatment of colon-related diseases, it is 
necessary to deliver a drug compound directly to the active site. This 
type of delivery systems makes the release and absorption of drugs 
do not occur in the upper gastrointestinal tract but occurs after the 
drug reaches the colon [1]. 
Drug delivery to the colon via oral route can be directly treated a 
variety of diseases in the colon, such as fibrosis. Fibrosis is a serious 
complication associated with ageing also to the chronic injury and 
inflammation in the organ. It is characterized by the normal 
architecture of organ damage by excessive deposition of 
extracellular matrix (ECM) [2]. Intestinal fibrosis (IF) is often 
associated with Crohn’s disease-an inflammatory bowel disease 
(IBD) resulting in the formation of structures, which will obstruct 
the intestinal lumen [3]. There are no drugs registered for the 
treatment of IF and the only currently available therapy is intestinal 
resection. Currently, there are several antifibrotic compounds under 
research, such as galunisertib [4], rosmarinic acid [5], and 
tetrandrine. We used tetrandrine as an anti-fibrotic drug model. 
Tetrandrine was an alkaloid isolated from Stephania tetrandra S. 
Moore root, studied as an inhibitor working in transforming growth 
factor (TGF)-β signalling pathway (TGF-inhibitor) [6]. Therefore, it 
was expected to have potential in intestinal fibrosis treatment.  
One approach for controlled release formulations is by using beads. 
Beads have functioned as a solid substrate coated or encapsulated 
drug in the core of the beads [7]. Beads can be used as a controlled 
drug delivery and drug-specific as well as to improve bioavailability 
and stability of the drug [8]. Some natural polymers that can be used 
for drug delivery to the colon, include chitosan, alginate, and pectin. 
Beads can be formed by utilizing the chitosan and a crosslinker such 
as sodium tripolyphosphate (TPP). TPP can interact with chitosan 
via ionic gelation method. Gelation method is based on the ability of 
cross-linked polyelectrolyte with the ions to form a hydrogel. 
Hydrogel beads are produced by dripping a polymer solution 
containing the drug into a solution that is an anion. Anions diffuse 
into the polymer droplets containing the drug, forming a three-
dimensional lattice of cross-sections that are connected by ionic [9]. 
In this study, we developed a colon-targeted preparation, such as 
tetrandrine beads for the treatment of fibrosis, using ionotropic 
gelation method, with chitosan as the polymer and TPP as the 
crosslinker, and also coating the beads using pH sensitive polymer 
i.e. Eudragit L100-55, Eudragit L100, hydroxypropyl methyl 
cellulose phthalate (HPMCP) HP-55 or cellulose acetate phthalate 
(CAP). The final beads then characterized and conducted a test to 
obtain the drug release profile in vitro and in vivo. 
MATERIALS AND METHODS 
Materials 
Tetrandrine (Shaanxi Ciyuan Biotech, China), sodium 
tripolyphosphate (Brataco, Indonesia), chitosan (Biotech Surindo, 
Indonesia), Eudragit L100-55 (Evonik, Germany; obtained from PT. 
Jebsen & Jessen Ingredients, Indonesia), Eudragit L100 (Evonik, 
Germany; obtained from PT. Jebsen & Jessen Ingredients, Indonesia), 
cellulose acetate phthalate (Eastman, USA; obtain from Eastman 
Chemical Company, Singapore), hydroxypropyl methyl cellulose 
phthalate HP-55 (Shin Etsu, Japan; obtained from PT Lawsim Zecha, 
Indonesia), talc (Brataco, Indonesia), triethyl citrate (Weifang Limin 
Chemical, China; obtained from PT. Lawsim Zecha, Indonesia), Tween 
80 (Brataco, Indonesia), chloride acid (Merck, Germany), potassium 
phosphate monobasic (Merck, Germany), sodium hydroxide (Merck, 
Germany), acetone (Brataco, Indonesia), isopropanol (Brataco, 
Indonesia), deionized water (Brataco, Indonesia). 
Animals: The Sprague-Dawley male rats with a weight of 260-330 g 
from Badan Penelitian dan Pengembangan Kesehatan (Balitbangkes, 
Indonesia) 
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Preparation of chitosan-tripolyphosphate beads 
Tetrandrine was dissolved in 0.5 N HCl pH 2, then mixed with 5% 
(w/v) chitosan solution. A solution of chitosan-tetrandrine then 
dripped slowly by using 26 G syringe needle into a solution of TPP 
pH 6.5 under 200 rpm stirring rate for 45 min. Beads obtained in 
TPP solution was stored for 30 min, then collected and rinsed with 
deionized water three times. After rinsing, beads were dried at 
room temperature (25 °C) for 48 h. All beads formulae can be seen 
in table 1. 
 
Table 1: Chitosan-tripolyphosphate beads formula 
Formula Chitosan (% w/v) Sodium tripolyphosphate (% w/v) Tetrandrine (% w/w)* Crosslink time (min) 
1 5 3 2.5 15 
2 5 4 2.5 15 
3 5 5 2.5 15 
*weight ratio between chitosan and tetrandrine (2:1) 
 
Beads coating process with pH-sensitive polymers 
Eudragit L100-55 was mixed with plasticizer and talc thus can be 
obtained 10% and 12.5% Eudragit L100-55. The plasticizer used 
was triethyl citrate in 25% concentration of Eudragit L100-55 mass 
used [10]. All coating materials then dissolved in acetone: 
isopropanol (1:1). Beads which would be coated were added to 
Eudragit L100-55 solutions while stirred. In beads coating with 
Eudragit L100, the coating was performed with a similar method 
and condition with Eudragit L100-55 for beads coating. 
For CAP, a 10% (w/v) and 15% (w/v) solution in acetone were used 
for coating and triethyl citrate (2.5%, w/w) was used as a plasticizer. 
In the case of coating with HPMCP, a 10% (w/v) and 12% (w/v) 
solution in acetone were used and triethyl citrate (2.5%, w/w) was 
used as a plasticizer. Coating formula can be seen in table 2. 
 
Table 2: Coating formula 
Formula Coating material Concentration (%, w/v) Plasticizer (%)* Talc (%)* Solvent 
A HPMCP 10 2.5 - Acetone 
B HPMCP 12 2.5 - Acetone 
C CAP 10 2.5 - Acetone 
D CAP 15 2.5 - Acetone 
E Eudragit L100-55 10 2.5 5 Acetone-Isopropanol (1:1) 
F Eudragit L100-55 12.5 3.125 6.25 Acetone-Isopropanol (1:1) 
G Eudragit L100 10 2.5 5 Acetone-Isopropanol (1:1) 
H Eudragit L100 12.5 3.125 6.25 Acetone-Isopropanol (1:1) 




Beads surface shape were observed using an optical microscope. 
Morphology 
Beads were coated with gold metal and put in the sample holder. 
The sample then observed under vacuum with scanning electron 
microscope (SEM; LEO 420i, United Kingdom). 
Particle size distribution 
The diameters of 300 beads were measured using an optical microscope. 
Water content 
Moisture content was determined using moisture balance (AMB 50, 
United Kingdom). One gram of the beads were weighed. The samples 
were then placed on the aluminium pan and dried completely at an 
elevated temperature until no further weight change was observed. 
Thermal test 
The test was performed using differential scanning calorimetry (DSC; 
PerkinElmer STA 6000, USA) on tetrandrine, pectin, CaCl2, calcium 
pectinate beads, also calcium pectinate beads containing tetrandrine. A 
total of 5.0 mg sample was put into a crucible 10.0 μl, then heated and 
measured from 25-300 °C with the heating rate was 10 °C/min. 
Nitrogen gas was used as purge gas with a 100 ml/min flow rate. 
X-ray diffraction 
X-ray diffraction (XRD) test (Philips PW 2213/20, The Netherlands) 
was performed on tetrandrine and calcium pectinate beads 
containing tetrandrine. The X-ray diffraction pattern was recorded 
using diffractometer X-ray radiation with Cu as the anode and 
graphite monochromatic, operate in 40 kV, 30 mA. 
Process efficiency 
Process efficiency was defined by comparing total dry beads weight 
obtained against total material used during the beads production. 
The recovery value could be obtained with this following formula:  
Process efficiency % =
Wm
Wt
× 100% 1 
Wm = Beads weight obtained (g) 
Wt = Total beads material weight (g) 
Entrapment efficiency 
Tetrandrine content test in the beads was performed by weighing 
carefully ± 50.0 mg beads, then soaked in 10.0 ml phosphate buffer 
pH 6.8 for 24 h. After 24 h, the solutions were stirred with a 
magnetic stirrer at 100 rpm and heated in 37 °C until they 
disintegrated. The disintegrated beads then mixed in phosphate 
buffer pH 6.8 with HCl 0.1 N addition until obtained 50.0 ml volume, 
then put into centrifuge tubes and separated from centrifugation 
device for 10 min at 2500 rpm. After separated, the supernatant was 
collected then adding HCl 0.1 N until obtaining 100.0 ml. Twenty 
millilitres solution was pipetted, put in 50.0 ml volumetric flask and 
adding phosphate buffer pH 6.8 until reaching the absorption limit. 
Tetrandrine absorption was measured using spectrophotometer UV-
Vis (Shimadzu UV-1800, Japan) at 280 nm wavelength. Tetrandrine 
content was measured by comparing the calibration curve thus the 
tetrandrine entrapped could be measured. 
Entrapment percentage (%EE) obtained by comparing the core total 
content obtained with the total core theoretic, was measured using 
the following formula:  
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Entrapment efficiency % =
Total core measured
Total core theoretic
× 100% 2 
Swelling test 
Two-point five-gram beads sample from each formula was weighed (W1) 
then placed on weighing dishes. Twenty-five millilitres phosphate buffer 
pH 6.8 was added and stayed aside to expand in the room temperature. 
After 5 min, the sample was collected from the container, carefully dried 
and the rest of the medium was absorbed by filter paper, then weighed 
(W2). After the sample had been weighed, they were put back into the 
medium. The weighing was following the same procedure which was 
performed in 5, 10, 15, 30, 60, 90, 120 and 180 min. swelling ability was 
measured using the following formula:  
Swelling ability % =
w2 − w1
w1
× 100% 3 
W1 = Dry sample weight 
W2 = Hydrated sample weight 
In vitro release study 
The in vitro release study was performed in hydrochloride acid 0.1 N pH 
1.2, phosphate buffer pH 7.4, and phosphate buffer pH 6.8 media. Media 
volume used was 200.0 ml in 37±0.5 °C using magnetic stirrer in 100 
rpm rate. The drug release time in chloride acid 0.1 N pH 1.2 medium 
was observed for 2 h, in phosphate buffer pH 7.4 medium was observed 
in 3 h and the phosphate buffer pH 6.8 medium was observed in 3 h. One 
hundred milligrams beads were weighed and put in the filter bag then 
put into the dissolution medium. Ten milliliters sample was collected, 
then the collected sample solution was immediately replaced with the 
same medium in some certain times. The absorption of the sample then 
measured using spectrophotometer UV-Vis. 
Measurement of the substance contained in the sample at n-minute 








y= tetrandrine absorption 
yn= tetrandrine absorption in n minute 
x= tetrandrine concentration 
fp= dissolution factor 
M= volume of release medium 
S= sampling volume 
a= intercept coefficient 
b= slope 
In vivo targeted test 
The in vivo targeted test was performed qualitatively to define the 
beads toleration against gastric and proximal intestine pH thus 
could reach the colon. The test was performed in the Sprague-
Dawley male rats with a weight of 260-330 g. prior to the 
experiment procedure, animals have been acclimatized for one 
week. Rats were placed in the cage with free access to their food 
and drink. The cage environment was controlled to minimize the 
humidity and the temperature was maintained around 25 °C. 
Furthermore, there was a dark and light cycle every 12 h. Each 
group of rats was placed in a separate cage and maintained in such 
a way so the rats did not interact with each other. The condition of 
the rats was monitored every day and the weight of rats was 
weighed every week. Before performing the test, we conducted 
time orientation of the dissection. Beads were mixed in ± 5.0 ml 
water and injected into the rats using gastric injection with the 
dissection times were 1, 1.5, 2, 2.5, and 3 h [11]. The beads tested 
on rats were beads with coating formula which provided the best 
in vitro release profile. Rats were separated into two groups, 
which were: (1) beads without coating as control and (2) beads 
with the best coating. The rats were dissected in the time 
determined before according to the orientation result and the 
colon condition was observed. Drugs targeted test was said 
successful if the beads found attached to the intestine. The 
experiments were approved by the Ethical Committee of Cipto 
Mangunkusumo Hospital, Faculty of Medicine, Universitas 
Indonesia with ethical approval Reg. No. 319/UN2. F1/ETIK/2016. 
RESULTS AND DISCUSSION 
Chitosan-tripolyphosphate beads 
Production was performed with 5% chitosan solution and the 
concentration of TPP (3%, 4%, and 5%) with tetrandrine and 
chitosan ratio used was 1:1. Chitosan in 5% concentration was 
dissolved in deionized water. Then tetrandrine was dissolved in HCl 
0.5 N. Chitosan and tetrandrine solutions were mixed and stirred 
until homogenous using stirrer. When the chitosan and tetrandrine 
mixtures were shed on TPP, beads would immediately have shaped 
by ionotropic gelation process. This process was happened because 
of the cross-linked between chitosan amine groups which had 
positive load and TPP with the negative ion [12]. 
Beads coated with pH-sensitive polymer 
Chitosan-TPP beads coating was performed to hold tetrandrine 
release in the upper part of gastrointestinal tract. This experiment 
was used Eudragit L100-55, Eudragit L100, HPMCP HP-55, or CAP. 
Chitosan-TPP beads containing dry tetrandrine were put into 
coating solution which had been thickened. After a continuous 
stirring, beads were separated from the coating solution, dried with 
a warm air, then separated one by one. 
Beads characterizations  
Beads shape 
According to the observation, the wet beads were found spherical in 
a yellowish clear color. After dried on filter paper at room 
temperature, the beads became brownish yellow, the size was 
changed and the beads visually still showed sphericall. These results 
can be seen in fig. 1. 
 
 
Fig. 1: The appearance of dry beads with varying concentrations of tripolyphosphate, a) Formula 1, b) Formula 2, c) Formula 3 
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According to the SEM results under 150x magnification (fig. 2), on 
Formula 2 and Formula 3 showed that TPP concentrations affected 
the beads surface characterization, where the higher the TPP 
concentrations then the beads obtained would be softer and got 




Fig. 2: SEM observation results under 150x magnification, a) Formula 1, b) Formula 2, c) Formula 3 
 
Particle size distribution 
Beads particle size distribution was evaluated using the optical 
microscope in 40x magnification. Formula 1 which was distributed 
in 907-944 μm was found in 33.33%, Formula 2 which was 
distributed in 900-973 μm was found in 44.33%, and Formula 3 
which was distributed in 1003-1028 μm was found in 30%. 
Coated particle beads size distribution evaluation also performed 
using an optical microscope. Formula 3E which was distributed in 
particle size 1820-1979 μm was found in 27%, Formula 3F which 
was distributed in particle size 1510-1669 μm was found in 28.33%, 
Formula 3G which was distributed in particle size 1510-1669 μm 
was found in 29.66%, Formula 3H which was distributed in particle 
size 1510-1669 μm was found in 28.66%.  
Based on the particle distribution results, the beads produced did 
not have a uniform particle size distribution. This could be caused by 
the pressure difference in the shedding process of chitosan and 
tetrandrine mixtures to the sodium tripolyphosphate solutions. The 
average beads diameter showed that the bigger size was obtained 
while using a higher concentration of sodium tripolyphosphate used. 
This proved that the big beads size could be affected by sodium 
tripolyphosphate concentration. The excess TPP ion may cause all 
part experience cross-link thus it would create a bigger bead, 
therefore the higher the sodium tripolyphosphate used then the 
bigger the beads size obtained [13, 14]. 
Water content 
Results of beads water content from the three formulae showed that 
the water contained was found between 5.64%-7.28%. Water content 
results towards the dry beads obtained from Formula 1, 2, and 3 were 
7.28±0.003%, 5.64±0.005%, and 6.84±0.004%, respectively. 
Process efficiency 
Process efficiency was calculated by comparing the total weight of 
the obtained dry beads to the total of raw materials used during 
preparation. Beads materials used were chitosan, tetrandrine, and 
sodium tripolyphosphate. The process efficiency process results of 
dry beads from Formula 1, 2, and 3 were 29.70%, 28.96%, and 
29.70%, respectively. 
The process efficiency showed the not too high results could be 
caused by the beads were experiencing size shrinkage after drying 
process, thus they lost moisture in the polymer which causing a 
lower dry beads weight. 
Entrapment efficiency 
Entrapment efficiency determination was calculated based on the 
concentration of tetrandrine in the beads. Entrapment efficiency was 
performed by soaking the beads in phosphate buffer medium pH 6.8 
so that the beads would expand and release the drugs. Then adding 
Tween 80 15% (w/v) to dissolve the tetrandrine. Entrapment 
efficiency obtained for Formula 1, 2, and 3 were 16.20±0.63%, 
17.02±0.37%, and 20.42±0.70%, respectively. All characterizations 
of core beads were described in table 3. 
Thermal test 
The thermal test was performed on tetrandrine, chitosan, sodium 
tripolyphosphate, chitosan-TPP beads, also chitosan-TPP containing 
tetrandrine. The test was performed using differential scanning 
calorimeter device. Results of tetrandrine thermogram showed an 
endothermic peak at 219.32 °C. Chitosan had one endothermic peak 
at 259.25 °C and two exothermic peaks at 300.57 °C and 855.69 °C. 
Sodium tripolyphosphate had four endothermic peaks which were at 
58.42 °C, 119.26 °C, 537.74 °C, and 621.97 °C. Chitosan-TPP beads 
showed an endothermic peak at 192.67 °C, while chitosan-TPP 
beads containing tetrandrine showed an endothermic peak at 
193.55 °C. These results were illustrated in fig. 3. 
On DSC thermogram of beads containing tetrandrine we found a 
different endothermic peak compared with thermogram of 
tetrandrine and empty beads, and with each beads material. A 
significant peak change in DSC thermogram confirmed that 
tetrandrine had experienced chemical interaction and had been 
entrapped into the beads. 
X-ray diffraction 
X-ray diffraction test was performed to detect the drug 
polymorphism after gelation process [15]. X-ray diffraction pattern 
of tetrandrine showed a dominant crystalline phase, this showed by 
sharp and tall diffractions. The decreased tetrandrine peak intensity 
can be found in chitosan-TPP beads containing tetrandrine, this 
showed that there was physical interaction. Tetrandrine was 
transformed from a crystalline phase to amorphous phase in 
chitosan-TPP beads (fig. 4). 
 
Table 3: Characterization of core beads 









1 920.50±0.04 7.28±0.003 29.70 16.20±0.63 
2 942.21±0.08 5.64±0.005 28.96 17.02±0.37 
3 1085.95±0.03 6.84±0.004 29.70 20.42±0.70 
*n=3; Data are expressed as mean±SD. 
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Fig. 3: DSC thermogram, a) tetrandrine, b) chitosan, c) sodium tripolyphosphate, d) chitosan-TPP beads with tetrandrine, e) chitosan-TPP 
beads without tetrandrine 
 
 
Fig. 4: Comparison of XRD patterns, a) chitosan-TPP beads containing tetrandrine, b) tetrandrine 
 
Swelling test 
The swelling ratio of beads was observed in HCl pH 1.2 medium for 3 
h at room temperature. The results showed that the beads expanded 
by 192.40%, 195.20%, and 199.20% for Formula 1, 2, and 3, 
respectively. On the other hand, the swelling ability of chitosan-TPP 
beads in phosphate buffer pH 6.8 medium was lower, i.e. 128%, 
132%, and 136% for Formula 1, 2, and 3, respectively. The swelling 
ratio was high at pH 1.2 in comparison to 6.8 which is in line with 
the earlier report by Srinatha et al. [12] 
Phosphate buffer pH 6.8 was used as a medium to simulate a colon 
fluid pH. The aim of swelling ability test was to define the ability of 
beads to swell when the beads had reached the colon. Based on the 
swelling test result, chitosan-TPP beads was better swell in the acid 
medium than in pH 6.8 medium. These results might cause by a 
chitosan-TPP contains-NH2 group which in the acidic conditions can 
be protonated into NH3+. Furthermore, because of this condition, 
made the chitosan became more hydrophilic, thus the chitosan-TPP 
could swell in the acidic medium [16]. 
In vitro release test 
In HCl pH 1.2 medium, beads with 10% and 15% CAP formulae 
showed the cumulative drug release were 5.45% and 2.76%. CAP in 
10% concentration could maintain a better drug release. However, 
beads with HPMCP could maintain a better drug release than CAP. 
The cumulative drug release in HCl medium for formula 3A was 
1.72% and 3B was 1.37%. In contrast, beads coated with 
methacrylate polymer (Eudragit) couldn’t resist tetrandrine 
released better than the phthalate polymer in acidic medium.  
In phosphate buffer pH 7.4, it was expected that the coat still could 
hold drug release. Absorption showed that the value was starting to 
increase. This showed that the drugs slowly had been released from 
the beads. The cumulative drug release in phosphate buffer pH 7.4 for 
Formula 3A was found in 68.10% and for Formula, 3B was found in 
66.47%. On the other hand, beads with CAP coat had lower release 
value, 43.62% and 36.64% for Formula 3C and 3D. In addition, beads 
with Eudragit L100 coat had a lower drug release compared with 
Eudragit L100-55, which was 19% for Formula 3G and 3H. 
In phosphate buffer pH 6.8, it was expected that the drugs would 
completely release. The drug release in minute 315 was increased 
significantly. This was caused by the coating layer which had been 
eroded and in phosphate buffer 6.8, beads could well expand thus it 
helped the drug release. In contrary, the drug release on beads with 
HPMCP coat had decreased. It might be all drug already released 
beforehand. Furthermore, beads with Eudragit–a methacrylate 
polymer–coat had a lower drug release compared with CAP or 
HPMCP–a phthalate polymer. 
After 8 h test, it can be concluded that beads coating either with 
methacrylate or phthalate polymer was sufficient to resist 
tetrandrine released in the upper gastrointestinal tract, but 
phthalate polymer could release more drug at pH 6,8 which was 
simulated as a colon. 
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Based on the in vitro results, beads with 15% CAP coat had the 
lowest drug release cumulative in HCl pH 1.2 and phosphate buffer 
pH 7.4. Then, when entering phosphate buffer medium pH 6.8, the 
drug release was significantly increased. Therefore, Formula 3D was 
chosen to be used in the in vivo targeted test. These results are 
demonstrated in fig. 5. 
 
 
Fig. 5: The cumulative drug release profile, a) formula 3A (HPMCP 10%), 3B (HPMCP 12%), 3C (CAP 10%), and 3D (CAP 15%), b) Formula 
3E (Eudragit L100-55 10%), 3F (Eudragit L100-55 12.5%), 3G (Eudragit L100 10%), and 3H (Eudragit L100 12.5%). n=3, data are 
expressed as mean±SD 
 
In vitro drug release was tested in hydrochloride acid pH 1.2 
medium as a gastric acid fluid simulation for 2 h, phosphate buffer 
pH 7.4 as small intestine fluid simulation for 3 h, and phosphate 
buffer pH 6.8 as colon fluid simulation for 3 h. This release test 
carried out without the presence of enzymes, while in fact, enzymes 
would trigger more drug release mechanism. 
In vivo targeted test 
Beads formula with CAP 15% coat was chosen as a formulation with 
the best in vitro profile which then used in in vivo drug targeted test 
using rats. Before the intervention, the rats were fasting for one day 
to clean the gastrointestinal tract from food or feces thus facilitate 
the observation. According to the time orientation, we chose 2.5 h as 
the most suitable dissection time for observation. Two and half 
hours after beads administration, rats were dissected and observed 
to define the colon condition. 
Conforming to the result of control rats, we found no beads in rat 
gastrointestinal tract, beads without a coat was expected had 
been degraded by gastric pH before reached the intestine. In rat 
1, we found beads at the half of the total intestine length; in rat 
2, we found beads at two-third of the total intestine length; then 
in rat 3, we found beads at three-fourth of the total intestine 
length. All beads in these conditions found expanded and we 
could not find any coat left. These results can be seen in fig. 6. 
Beads found in rat gastrointestinal tract showed coated beads 
toleration against pH of the upper gastrointestinal tract. Also, 




Fig. 6: Beads appearance after the in vivo test, a) rat 1, b) rat 2, c) rat 3 
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Together, it can be concluded that the best formulation based on the 
characterizations was Formula 3 (5% of TPP concentration). Formula 
3 had an average size of 1.085±0.03 µm, water content was 6.84%, and 
the entrapment efficiency was 20.42±0.70%. Formula 3 was then 
coated with HPMCP HP-55, CAP, Eudragit L100-55 or Eudragit L100. 
In addition, in vitro release study showed that beads which were 
coated with CAP 15% could hold the drug release in the upper 
gastrointestinal tract better than others. Formula 3D (beads coated 
with 15% CAP) was chosen as a formulation with the best in vitro 
profile which showed an optimal protection from gastric acid. 
Moreover, the in vivo targeted test showed that Formula 3D could 
deliver the tetrandrine to the intestine compared to the control beads. 
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